ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Postoperative Delirium With Donepezil

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00220896
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : September 14, 2011
Sponsor:
Collaborator:
Eisai GmbH, Frankfurt, Germany
Information provided by:
Technische Universität München

Brief Summary:
Patients undergoing hip or knee joint replacement at the age of 70 years or above who are cognitively unimpaired will receive donepezil or matching placebo before (over 5-7 days), during and after (over 7 days) surgery. The incidence of delirium will be monitored at 3 days, 7 days, and 49 days following surgery. We hypothesize that the incidence of delirium can be lowered from 20 per cent to 10 per cent by the intervention.

Condition or disease Intervention/treatment Phase
Cognitively Normal Elderly Individuals Drug: Donepezil Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Study Start Date : January 2006
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Delirium
U.S. FDA Resources




Primary Outcome Measures :
  1. Incidence of delirium

Secondary Outcome Measures :
  1. Cognitive performance


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cognitively healthy, elective hip or knee replacement

Exclusion Criteria:

  • Ongoing cholinergic treatment, dementia, delirium, acute physical illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00220896


Locations
Germany
Deps. of Psychiatry and Anaesthesiology, Tech. Universitaet Munich
Munich, Germany, D-81675
Sponsors and Collaborators
Technische Universität München
Eisai GmbH, Frankfurt, Germany
Investigators
Principal Investigator: Janine Diehl, M. D. Dept. of Psychiatry, Technische Universitaet Muenchen

ClinicalTrials.gov Identifier: NCT00220896     History of Changes
Other Study ID Numbers: PSYTUM1
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: September 14, 2011
Last Verified: September 2011

Keywords provided by Technische Universität München:
Delirium
Prevention
Donepezil

Additional relevant MeSH terms:
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents